News Release

Oct. 09, 2008

About the transfer of approval to production and marketing of ASTAT®, an external-use, anti-fungal drug for ethical use

Tsumura & Co. (Headquarters: Tokyo, President: Junichi Yoshii) today announces a trilateral agreement on the transfer of approval to the production and marketing of ASTAT? (generic name: Lanoconazole), an external-use anti-fungal drug for ethical use, to Maruho Co., Ltd. (Head office: Osaka, President: Koichi Takagi. Hereinafter "Maruho"). ASTAT? is jointly developed by Tsumura and Nihon Nohyaku Co., Ltd. (Head office: Tokyo, President: Shukichi Ohuchi. Hereinafter "Nihon Nohyaku") and is made and marketed by Tsumura.

Since September 1994, Tsumura has marketed ASTAT? by receiving drug substances from Nihon Nohyaku. Available in three forms including ASTAT? Cream, ASTAT? Solution and ASTAT? Ointment, ASTAT? is extensively used in the treatment of many patients.
At present, Tsumura markets ASTAT? Cream, ASTAT? Solution and ASTAT? Ointment. The above agreement will allow Maruho, from next spring, to market all of the three forms of ASTAT?, send related information to medical institutions and gather that information.